IQVIA has announced a partnership with Janssen Research & Development, LLC. They will work together to carry out a Phase 3 clinical trial using Janssen's COVID-19 vaccine. Informative RWD (real world data) will be collected and utilized in assessing vaccine efficacy.
“The studies leverage IQVIA's suite of decentralized trial solutions that support both on-site and remote study delivery through a mix of telehealth technologies, virtual oversight, and digital patient engagement strategies. These capabilities enabled participants to be screened remotely to determine their risk status, to schedule an appointment at a nearby site, and to report potential COVID-19 symptoms and other study data remotely throughout the study.” Read more here.
(Source: IQVIA, 3/8/21)
